Leading Off: Pharmaceuticals in the Dry Eye Disease Pipeline - Takeaways - MDSpire

Leading Off: Pharmaceuticals in the Dry Eye Disease Pipeline

New innovations targeting dry eye disease (DED) are in the pipeline to enable us to tailor our treatments to the specific underlying causes of DED.

  • By

  • SHANE R. KANNARR, OD

  • Christoper J. Jacquinot, OD

  • Ryan A. Cedeno, OD

  • July 1, 2025

  • 1 min

Share

  • 1

    Reproxalap is a reactive aldehyde species modulator in phase 3 trials, targeting inflammation in dry eye disease and allergies.

  • 2

    AZR-MD-001 is an ophthalmic ointment in phase 3 trials aimed at improving meibum quality in patients with meibomian gland dysfunction.

  • 3

    OCS-02, an anti-TNFa drop in phase 2 trials, is designed to treat ocular inflammation and apoptosis related to dry eye disease.

  • 4

    Softacort, currently in phase 4 trials, is an anti-inflammatory that may relieve symptoms of meibomian gland dysfunction.

  • 5

    New treatments for dry eye disease are being developed to address specific underlying causes, enhancing personalized patient care.

Original Source(s)

Leading Off: Pharmaceuticals in the Dry Eye Disease Pipeline

  • by SHANE R. KANNARR, OD, Christoper J. Jacquinot, OD, Ryan A. Cedeno, OD

  • July 1, 2025

Related Content

Look Again! Demodex Blepharitis in Closer Focus

Why Demodex blepharitis deserves more attention – and how a quick diagnostic check can improve patient care

  • January 19, 2026

  • 7 min
Dry Eye After Cataract Surgery

Scientific Reports study compares dry eye effects of phacoemulsification and MSICS

  • February 16, 2026

  • 3 min
Blending Ocular Health and Aesthetics: Emerging Procedures for Optometric Practice

Eyecare professionals can address functional symptoms of ocular disease, as well as periocular aesthetic care and cosmetic concerns, in both separate and combined treatment frameworks, Selena McGee, OD, FAAO, Janelle Davison, OD, and Shalu Pal, OD, said in their “Beauty in Focus: Elevating Eyecare Through Ocular Aesthetics” presentation at Vision Expo.